ESR1 and breast cancer: Among breast cancer subgroups this SNP was associated with reduced risk in premenopausal women (1353 subjects; summary OR: .73, CI: .59-.91, P=.005) and in ER/PR positive subgroup (3176 subjects; summary OR: .86, CI: .75-.99, P=.04) with an intermediate level of evidence.